Drug intelligence / Profile preview

tedalinab

Development stage: Unknown
Lead developer: Glenmark Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Tedalinab (GRC-10693) is a potent and highly selective small molecule agonist of the cannabinoid CB2 receptor, developed by Glenmark Pharmaceuticals. It demonstrates approximately 4700-fold selectivity for CB2 over the CB1 receptor, a profile intended to provide analgesic and anti-inflammatory benefits while avoiding the psychotropic side effects associated with CB1 activation. The drug was investigated for the treatment of chronic pain conditions, including neuropathic pain and osteoarthritis. Although it successfully completed Phase I clinical trials in Europe in 2009, which evaluated its safety, tolerability, and pharmacokinetics, no further clinical development has been publicly disclosed.

Other names: tedalinab

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on tedalinab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tedalinab.

Explore the full profile